Symbols / SXTP
SXTP Chart
About
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.99M |
| Enterprise Value | 8.76M | Income | -8.48M | Sales | 1.36M |
| Book/sh | -5.01 | Cash/sh | 3.89 | Dividend Yield | — |
| Payout | 0.00% | Employees | 3 | IPO | — |
| P/E | — | Forward P/E | -0.39 | PEG | — |
| P/S | 2.92 | P/B | -0.62 | P/C | — |
| EV/EBITDA | -1.12 | EV/Sales | 6.42 | Quick Ratio | 2.18 |
| Current Ratio | 2.87 | Debt/Eq | 3.54 | LT Debt/Eq | — |
| EPS (ttm) | -3.10 | EPS next Y | -7.88 | EPS Growth | — |
| Revenue Growth | 256.90% | Earnings | 2025-11-13 13:00 | ROA | -70.04% |
| ROE | -154.77% | ROIC | — | Gross Margin | 42.92% |
| Oper. Margin | -4.40% | Profit Margin | 0.00% | Shs Outstand | 1.29M |
| Shs Float | 937.14K | Short Float | 16.49% | Short Ratio | 0.02 |
| Short Interest | — | 52W High | 17.68 | 52W Low | 1.36 |
| Beta | 2.96 | Avg Volume | 3.52M | Volume | 10.77K |
| Target Price | $17.60 | Recom | None | Prev Close | $3.06 |
| Price | $3.10 | Change | 1.31% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$17.60
Mean price target
2. Current target
$3.10
Latest analyst target
3. DCF / Fair value
$-55.60
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.10
Low
$11.20
High
$24.00
Mean
$17.60
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-27 | main | HC Wainwright & Co. | Buy → Buy | $24 |
| 2025-11-28 | main | Ascendiant Capital | Buy → Buy | $3 |
| 2025-09-03 | main | Ascendiant Capital | Buy → Buy | $3 |
| 2025-06-02 | main | Ascendiant Capital | Buy → Buy | $7 |
| 2025-03-28 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-02-25 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-01-10 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-12-23 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-12-11 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-11-15 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-09-13 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-08-15 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-06-06 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-04-03 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2023-10-20 | init | HC Wainwright & Co. | — → Neutral | — |
| 2023-10-02 | init | Ascendiant Capital | — → Buy | $2 |
- 60 Degrees Pharmaceuticals (SXTP) Partners With GoodRx to Expand Access to ARAKODA - Yahoo Finance ue, 24 Feb 2026 18
- Telehealth deal lets U.S. travelers secure weekly malaria prevention pre-trip - Stock Titan hu, 22 Jan 2026 08
- Here’s Why 60 Degrees Pharmaceuticals Stock (SXTP) Rocketed Today - TipRanks hu, 22 Jan 2026 08
- $SXTP stock is up 8% today. Here's what we see in our data. - Quiver Quantitative Wed, 28 Jan 2026 08
- 60 Degrees Pharmaceuticals Regains Nasdaq Listing Compliance Status - The Globe and Mail Fri, 13 Feb 2026 08
- SXTP Stock Rockets 161% Pre-Market — What Is Driving The Surge? - Stocktwits hu, 22 Jan 2026 08
- Dow, 60 degrees Pharmaceuticals CEO, buys $12k in SXTP stock - Investing.com Fri, 12 Dec 2025 08
- 60 Degrees Pharmaceuticals (SXTP) Price Target Increased by 300.00% to 17.95 - Nasdaq Wed, 04 Feb 2026 08
- SXTP Stock Sees Price Target Boost to $24 by HC Wainwright & Co. - GuruFocus ue, 27 Jan 2026 08
- Nasdaq-listed 60 Degrees Pharma shrinks shares 4-for-1 on Jan. 20 reverse - Stock Titan hu, 15 Jan 2026 08
- Here's Why 60 Degrees Pharmaceuticals Inc. (SXTP) Looks Ripe for Bottom Fishing - Yahoo Finance ue, 23 Dec 2025 08
- 60 Degree Pharmaceuticals Announces One-for-Four Reverse Stock Split Effective January 20, 2026 - Quiver Quantitative hu, 15 Jan 2026 08
- 60 Degrees Pharmaceuticals Faces Immediate Nasdaq Delisting Appeal - TipRanks Fri, 23 Jan 2026 08
- 60 Degrees Pharmaceuticals faces Nasdaq delisting after minimum bid price violation - Investing.com Fri, 23 Jan 2026 08
- Australian chestnut extract targets US non-Rx market with 60 Degrees Pharma - Stock Titan Wed, 28 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 9670 | 7759.0 | — | Purchase at price 0.80 per share. | DOW GEOFFREY S | Chief Executive Officer | — | 2025-12-15 00:00:00 | D |
| 1 | 12963 | 12204.0 | — | Purchase at price 0.92 - 0.95 per share. | DOW GEOFFREY S | Chief Executive Officer | — | 2025-12-11 00:00:00 | D |
| 2 | 7201 | 9996.0 | — | Stock Award(Grant) at price 1.39 per share. | DOW GEOFFREY S | Chief Executive Officer | — | 2025-09-12 00:00:00 | D |
| 3 | 4376 | 13065.0 | — | Stock Award(Grant) at price 2.99 per share. | DOW GEOFFREY S | Chief Executive Officer | — | 2025-06-09 00:00:00 | D |
| 4 | 5000 | 14410.0 | — | Purchase at price 2.87 - 2.90 per share. | XU CHERYL | Director | — | 2025-06-03 00:00:00 | D |
| 5 | 14394 | nan | — | — | DOW GEOFFREY S | Chief Executive Officer | — | 2025-01-17 00:00:00 | D |
| 6 | 11626 | nan | — | — | MILLER TYRONE | Chief Financial Officer | — | 2025-01-17 00:00:00 | D |
| 7 | 4540 | nan | — | — | LANDON KRISTEN | Chief Operating Officer | — | 2025-01-17 00:00:00 | D |
| 8 | 13000 | 21400.0 | — | Purchase at price 1.45 - 1.85 per share. | XU CHERYL | Director | — | 2024-12-16 00:00:00 | D |
| 9 | 73951 | 89755.0 | — | Purchase at price 1.11 - 1.27 per share. | DOW GEOFFREY S | Chief Executive Officer | — | 2024-12-09 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | -350.38K | -82.79K | 0.00 |
| TaxRateForCalcs | 0.00 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -9.55M | 241.94K | -1.71M | -1.01M |
| TotalUnusualItems | 1.67M | -1.67M | -394.24K | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 1.67M | -1.67M | -394.24K | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -7.95M | -3.77M | -6.18M | -4.25M |
| ReconciledDepreciation | 63.74K | 100.37K | 78.79K | 71.78K |
| ReconciledCostOfRevenue | 384.76K | 474.55K | 432.37K | 850.74K |
| EBITDA | -7.88M | -1.43M | -2.11M | -1.01M |
| EBIT | -7.95M | -1.53M | -2.19M | -1.09M |
| NetInterestIncome | -7.91K | -2.29M | -3.99M | -3.17M |
| InterestExpense | 7.91K | 2.29M | 3.99M | 3.17M |
| NormalizedIncome | -9.61M | -2.45M | -5.87M | -4.25M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -7.95M | -3.77M | -6.18M | -4.25M |
| TotalExpenses | 10.32M | 5.41M | 1.97M | 2.28M |
| TotalOperatingIncomeAsReported | -9.71M | -5.15M | -1.75M | -1.12M |
| DilutedAverageShares | 113.64K | 16.58K | 23.21K | 23.21K |
| BasicAverageShares | 113.64K | 16.58K | 23.21K | 23.21K |
| DilutedEPS | -74.20 | -236.72 | -266.38 | -183.22 |
| BasicEPS | -74.20 | -236.72 | -266.38 | -183.22 |
| DilutedNIAvailtoComStockholders | -7.95M | -3.77M | -6.18M | -4.25M |
| NetIncomeCommonStockholders | -7.95M | -3.77M | -6.18M | -4.25M |
| NetIncome | -7.95M | -3.77M | -6.18M | -4.25M |
| MinorityInterests | 8.56K | 48.10K | -3.94K | 8.55K |
| NetIncomeIncludingNoncontrollingInterests | -7.96M | -3.81M | -6.18M | -4.26M |
| NetIncomeContinuousOperations | -7.96M | -3.81M | -6.18M | -4.26M |
| TaxProvision | 250.00 | 250.00 | 500.00 | 1.00K |
| PretaxIncome | -7.96M | -3.81M | -6.18M | -4.26M |
| OtherIncomeExpense | 1.77M | 3.63M | -437.48K | 37.52K |
| OtherNonOperatingIncomeExpenses | 101.46K | 5.30M | -43.24K | 37.52K |
| SpecialIncomeCharges | 0.00 | -1.23M | 120.68K | 0.00 |
| OtherSpecialCharges | 1.23M | -120.68K | ||
| GainOnSaleOfSecurity | 1.67M | -437.00K | -514.92K | |
| NetNonOperatingInterestIncomeExpense | -7.91K | -2.29M | -3.99M | -3.17M |
| InterestExpenseNonOperating | 7.91K | 2.29M | 3.99M | 3.17M |
| OperatingIncome | -9.71M | -5.15M | -1.75M | -1.12M |
| OperatingExpense | 9.94M | 4.93M | 1.54M | 1.43M |
| OtherOperatingExpenses | -73.77K | -288.00K | -5.19M | |
| ResearchAndDevelopment | 4.99M | 691.77K | 525.56K | 5.51M |
| SellingGeneralAndAdministration | 5.02M | 4.24M | 1.30M | 1.12M |
| GeneralAndAdministrativeExpense | 5.02M | 4.24M | 1.30M | 1.12M |
| OtherGandA | 5.02M | 4.24M | 1.30M | 1.12M |
| GrossProfit | 222.81K | -220.98K | -209.16K | 309.60K |
| CostOfRevenue | 384.76K | 474.55K | 432.37K | 850.74K |
| TotalRevenue | 607.57K | 253.57K | 223.21K | 1.16M |
| OperatingRevenue | 607.57K | 253.57K | 223.21K | 1.16M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 141.73K | 24.21K | 23.21K | 23.21K |
| ShareIssued | 141.73K | 24.21K | 23.21K | 23.21K |
| NetDebt | 22.14M | 18.63M | ||
| TotalDebt | 155.89K | 172.67K | 22.42M | 18.80M |
| TangibleBookValue | -5.69M | -5.22M | -23.74M | -17.69M |
| InvestedCapital | -5.38M | -4.83M | -1.17M | 1.17M |
| WorkingCapital | 3.73M | 4.41M | -22.82M | 541.20K |
| NetTangibleAssets | 3.88M | 4.64M | -23.74M | -17.69M |
| CapitalLeaseObligations | 0.00 | 13.65K | 13.00K | 59.80K |
| CommonStockEquity | -5.53M | -4.99M | -23.58M | -17.58M |
| PreferredStockEquity | 9.57M | 9.86M | ||
| TotalCapitalization | 4.18M | 5.02M | -22.31M | 1.17M |
| TotalEquityGrossMinorityInterest | 3.96M | 4.80M | -24.15M | -18.15M |
| MinorityInterest | -80.59K | -72.04K | -572.32K | -576.26K |
| StockholdersEquity | 4.04M | 4.87M | -23.58M | -17.58M |
| GainsLossesNotAffectingRetainedEarnings | 135.47K | 135.56K | 73.71K | 75.83K |
| OtherEquityAdjustments | 135.47K | 135.56K | 73.71K | 75.83K |
| RetainedEarnings | -40.53M | -32.58M | -28.82M | -22.63M |
| AdditionalPaidInCapital | 34.86M | 27.46M | 5.16M | 0.00 |
| CapitalStock | 9.57M | 9.86M | 239.00 | 4.98M |
| CommonStock | 57.00 | 10.00 | 239.00 | 4.98M |
| PreferredStock | 9.57M | 9.86M | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 1.80M | 2.99M | 25.45M | 19.55M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 147.12K | 150.25K | 1.53M | 18.91M |
| DuetoRelatedPartiesNonCurrent | 0.00 | |||
| TradeandOtherPayablesNonCurrent | 0.00 | |||
| NonCurrentDeferredLiabilities | 0.00 | 255.00K | 154.74K | |
| NonCurrentDeferredRevenue | 0.00 | 255.00K | 154.74K | |
| LongTermDebtAndCapitalLeaseObligation | 147.12K | 150.25K | 1.27M | 18.76M |
| LongTermCapitalLeaseObligation | 0.00 | 13.00K | ||
| LongTermDebt | 147.12K | 150.25K | 1.27M | 18.74M |
| CurrentLiabilities | 1.66M | 2.84M | 23.92M | 635.47K |
| OtherCurrentLiabilities | 640.83K | 2.31M | 1.49M | 3.13K |
| CurrentDeferredLiabilities | 0.00 | 325.00K | 0.00 | |
| CurrentDeferredRevenue | 0.00 | 325.00K | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 8.77K | 22.42K | 21.15M | 46.80K |
| CurrentCapitalLeaseObligation | 0.00 | 13.65K | 13.00K | 46.80K |
| CurrentDebt | 8.77K | 8.77K | 21.14M | |
| OtherCurrentBorrowings | 8.77K | 8.77K | 16.86M | |
| CurrentNotesPayable | 0.00 | 4.28M | 0.00 | |
| PayablesAndAccruedExpenses | 1.01M | 506.21K | 953.76K | 588.68K |
| Payables | 1.01M | 506.21K | 953.76K | 588.68K |
| OtherPayable | 47.09K | |||
| DuetoRelatedPartiesCurrent | 0.00 | 195.10K | 0.00 | |
| TotalTaxPayable | 1.00K | |||
| IncomeTaxPayable | 1.00K | |||
| AccountsPayable | 1.01M | 506.21K | 758.67K | 588.68K |
| TotalAssets | 5.76M | 7.78M | 1.30M | 1.39M |
| TotalNonCurrentAssets | 373.07K | 541.18K | 198.20K | 216.85K |
| NonCurrentPrepaidAssets | 66.18K | 242.65K | 0.00 | 6.03K |
| GoodwillAndOtherIntangibleAssets | 157.08K | 227.26K | 164.25K | 109.24K |
| OtherIntangibleAssets | 157.08K | 227.26K | 164.25K | 109.24K |
| NetPPE | 149.81K | 71.28K | 33.95K | 107.61K |
| AccumulatedDepreciation | -149.43K | -148.06K | -126.90K | -99.25K |
| GrossPPE | 299.24K | 219.34K | 160.85K | 206.87K |
| OtherProperties | 233.41K | 146.43K | 145.56K | 191.58K |
| MachineryFurnitureEquipment | 65.83K | 72.91K | 15.29K | 15.29K |
| CurrentAssets | 5.39M | 7.24M | 1.10M | 1.18M |
| OtherCurrentAssets | 1.07M | 4.40M | 200.97K | 225.87K |
| CurrentDeferredAssets | 1.73M | 0.00 | 68.63K | 0.00 |
| PrepaidAssets | 200.97K | 225.87K | ||
| Inventory | 442.76K | 466.17K | 518.58K | 689.04K |
| InventoriesAdjustmentsAllowances | 0.00 | -160.34K | -38.32K | |
| FinishedGoods | 157.88K | 187.18K | 183.94K | 37.51K |
| WorkInProcess | 284.88K | 278.99K | 97.49K | 88.47K |
| RawMaterials | 0.00 | 397.49K | 601.38K | |
| Receivables | 486.75K | 231.33K | 45.97K | 146.36K |
| AccountsReceivable | 486.75K | 231.33K | 45.97K | 146.36K |
| CashCashEquivalentsAndShortTermInvestments | 1.66M | 2.14M | 264.87K | 115.40K |
| CashAndCashEquivalents | 1.66M | 2.14M | 264.87K | 115.40K |
| CashFinancial | 1.66M | 2.14M | 264.87K | 115.40K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -5.83M | -4.66M | -1.07M | -684.50K |
| RepaymentOfDebt | 0.00 | -1.61M | 0.00 | -72.00K |
| IssuanceOfDebt | 0.00 | 650.00K | 1.10M | 683.23K |
| IssuanceOfCapitalStock | 7.04M | 6.30M | 0.00 | |
| CapitalExpenditure | -181.11K | -115.89K | -60.13K | -35.39K |
| InterestPaidSupplementalData | 8.77K | 179.12K | 2.19K | 0.00 |
| IncomeTaxPaidSupplementalData | 2.00K | 1.00K | 1.00K | 750.00 |
| EndCashPosition | 1.66M | 2.14M | 264.87K | 115.40K |
| BeginningCashPosition | 2.14M | 264.87K | 115.40K | 191.70K |
| EffectOfExchangeRateChanges | 499.00 | 61.85K | -2.13K | -3.03K |
| ChangesInCash | -483.63K | 1.82M | 151.59K | -73.27K |
| FinancingCashFlow | 7.05M | 6.47M | 1.22M | 611.23K |
| CashFlowFromContinuingFinancingActivities | 7.05M | 6.47M | 1.22M | 611.23K |
| NetOtherFinancingCharges | -150.42K | 116.71K | ||
| ProceedsFromStockOptionExercised | 10.96K | 1.13M | 0.00 | |
| NetCommonStockIssuance | 7.04M | 6.30M | 0.00 | |
| CommonStockIssuance | 7.04M | 6.30M | 0.00 | |
| NetIssuancePaymentsOfDebt | 0.00 | -961.11K | 1.10M | 611.23K |
| NetLongTermDebtIssuance | 0.00 | -961.11K | 1.10M | 611.23K |
| LongTermDebtPayments | 0.00 | -1.61M | 0.00 | -72.00K |
| LongTermDebtIssuance | 0.00 | 650.00K | 1.10M | 683.23K |
| InvestingCashFlow | -1.89M | -115.89K | -60.13K | -35.39K |
| CashFlowFromContinuingInvestingActivities | -1.89M | -115.89K | -60.13K | -35.39K |
| NetInvestmentPurchaseAndSale | -1.71M | 0.00 | ||
| PurchaseOfInvestment | -1.71M | 0.00 | ||
| NetIntangiblesPurchaseAndSale | -25.37K | -18.28K | -27.07K | 0.00 |
| PurchaseOfIntangibles | -25.37K | -18.28K | -27.07K | 0.00 |
| NetPPEPurchaseAndSale | -103.77K | -57.62K | 0.00 | -3.07K |
| PurchaseOfPPE | -103.77K | -57.62K | 0.00 | -3.07K |
| CapitalExpenditureReported | -51.97K | -39.98K | -33.06K | -32.32K |
| OperatingCashFlow | -5.65M | -4.54M | -1.01M | -649.11K |
| CashFlowFromContinuingOperatingActivities | -5.65M | -4.54M | -1.01M | -649.11K |
| ChangeInWorkingCapital | 192.72K | 405.36K | 3.37M | 2.90M |
| ChangeInOtherWorkingCapital | -100.00K | 425.26K | 51.73K | |
| ChangeInOtherCurrentLiabilities | -13.65K | -50.27K | -46.80K | -39.82K |
| ChangeInPayablesAndAccruedExpense | 477.81K | 1.05M | 2.86M | 1.72M |
| ChangeInAccruedExpense | -23.60K | 1.27M | 2.69M | 2.57M |
| ChangeInInterestPayable | -23.60K | 1.27M | 2.69M | |
| ChangeInPayable | 501.41K | -214.73K | 169.99K | -844.67K |
| ChangeInAccountPayable | 501.41K | -214.73K | 169.99K | -844.67K |
| ChangeInPrepaidAssets | -39.42K | -522.37K | 24.90K | 135.84K |
| ChangeInInventory | 23.41K | 212.75K | 10.13K | 312.23K |
| ChangeInReceivables | -255.42K | -185.37K | 100.40K | 713.06K |
| ChangesInAccountReceivables | -255.42K | -185.37K | 100.40K | 713.06K |
| OtherNonCashItems | -4.48M | 1.16M | 604.60K | |
| StockBasedCompensation | 3.61M | 1.74M | 0.00 | |
| ProvisionandWriteOffofAssets | 0.00 | -160.34K | 160.34K | 38.32K |
| AssetImpairmentCharge | 108.42K | 0.00 | ||
| DepreciationAmortizationDepletion | 63.74K | 100.37K | 78.79K | 71.78K |
| DepreciationAndAmortization | 63.74K | 100.37K | 78.79K | 71.78K |
| AmortizationCashFlow | 38.50K | 29.16K | 5.12K | 3.31K |
| AmortizationOfIntangibles | 38.50K | 29.16K | 5.12K | 3.31K |
| Depreciation | 25.24K | 71.22K | 73.67K | 68.47K |
| OperatingGainsLosses | -1.67M | 1.67M | 394.24K | |
| GainLossOnInvestmentSecurities | -1.67M | 437.00K | 514.92K | |
| NetIncomeFromContinuingOperations | -7.96M | -3.81M | -6.18M | -4.26M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SXTP
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|